Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ATAI
$4.37
$
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Next Earnings
2026-02-25
Beta
1.615
Average Volume
Market Cap
Last Dividend
CIK
0001840904
ISIN
US04650F1012
CUSIP
N0731H103
CEO
Srinivas G. Rao
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full Time Employees
54
IPO Date
2021-06-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| AtaiBeckley To Host Virtual Investor Day on March 6, 2026 | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. | GlobeNewsWire | 2026-02-20 07:00:00 |
| Asara Resources extends high-grade corridor at Massan with 54m at 2.3 g/t gold | Asara Resources Ltd (ASX:AS1, OTC:GMRMF) has extended high-grade gold mineralisation at its Massan deposit within the company’s flagship Kada Gold Project... | Proactive Investors - Finance | 2026-02-20 05:51:00 |
| US economy grew at half the expected pace in the fourth quarter, dragging futures lower | US stock futures slipped further into negative territory after data showed the American economy expanded at an annualised rate of just 1.4% in the final... | Proactive Investors - Finance | 2026-02-20 03:55:00 |
| AtaiBeckley names Michael Faerm as finance chief | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25 years of experience spanning life sciences firms, equity research and investment banking. | Proactive Investors | 2026-02-19 08:27:13 |
| AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies | Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, with AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) a direct beneficiary. As reported by J&J on Wednesday, Spravato's fourth quarter 2025 sales in treatment-resistant depression (TRD) rose 10% sequentially to $503 million worldwide. | Proactive Investors | 2026-01-21 13:00:15 |
| AtaiBeckley seen as key beneficiary of Spravato’s strong growth: Jefferies | Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful... | Proactive Investors - Finance | 2026-01-21 07:58:00 |
| High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 | Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements. | MarketBeat | 2026-01-19 11:28:36 |
| AtaiBeckley shares clinical and preclinical data at ACNP Annual Meeting | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The Bahamas, where the company presented two scientific posters and delivered a Hot Topic Presentation. The clinical-stage biotechnology company said the presentations included new clinical and preclinical data related to its mental health development programs. | Proactive Investors | 2026-01-16 09:24:30 |
| AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation | NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical data supporting its development of transformative mental health therapies in two poster presentations and a Hot Topic Presentation. | GlobeNewsWire | 2026-01-16 07:00:00 |
| New Strong Sell Stocks for Jan. 13 | ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026. | Zacks Investment Research | 2026-01-13 05:05:14 |
| Mesoblast reports $US35.1m in gross revenue from sales of its cell therapy Ryoncil | Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) reported $US35.1 million ($52.4 million) in gross revenue from Ryoncil sales in the December quarter, up 60% on the... | Proactive Investors - Finance | 2026-01-09 05:14:00 |
| AtaiBeckley issues 2026 outlook, flags multiple clinical milestones | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has outlined its outlook for 2026, highlighting anticipated clinical milestones and recent corporate developments ahead of its participation in the JP Morgan 44th Annual Healthcare Conference in San Francisco later this month. The clinical-stage biotechnology company said it enters 2026 following the completion of the strategic combination of atai Life Sciences and Beckley Psytech, and its recent redomiciliation to the United States. | Proactive Investors | 2026-01-08 08:59:20 |
| AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference | NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. | GlobeNewsWire | 2026-01-08 07:00:00 |
| AtaiBeckley completes redomiciliation from Netherlands to US | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4. | Proactive Investors | 2025-12-31 08:31:07 |
| UiPath to be added to S&P MidCap 400, shares jump | UiPath Inc (NYSE:PATH) shares jumped 6% on the news that the automation platform will be added to the S&P MidCap 400 prior to the opening of trading on... | Proactive Investors - Finance | 2025-12-24 04:32:00 |
| AtaiBeckley joins the Nasdaq Biotechnology Index | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22. The NBI is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market that meet specific eligibility criteria, including minimum market capitalization, average daily trading volume and seasoning as a public company. | Proactive Investors | 2025-12-23 08:40:49 |
| AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) | NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. | GlobeNewsWire | 2025-12-23 07:00:00 |
| AtaiBeckley receives new US patent for oral R-MDMA formulation EMP-01 | AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that the US Patent and Trademark Office has granted a new patent covering EMP-01, its oral R-MDMA formulation. The company said that the patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043. | Proactive Investors | 2025-12-11 09:16:31 |
| Nasdaq tumbles as AI stocks retreat after Oracle earnings | 9.55am: AI and semiconductors lead Nasdaq lower at open Investors moved money out of US tech stocks on Thursday. It was a mixed picture overall on Wall... | Proactive Investors - Finance | 2025-12-11 04:55:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 15-12G | 2025-12-31 | 2025-12-30 | View Filing |
| POSASR | 2025-12-31 | 2025-12-30 | View Filing |
| S-8 POS | 2025-12-31 | 2025-12-30 | View Filing |
| 8-K | 2025-12-05 | 2025-12-05 | View Filing |
| 424B7 | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 3 | 2025-11-06 | 2025-11-06 | View Filing |
| 3 | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| 424B7 | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-04 | 2025-11-04 | View Filing |
| SC 13D/A | 2025-10-29 | 2025-10-29 | View Filing |
| 425 | 2025-10-27 | 2025-10-24 | View Filing |
| 8-K | 2025-10-27 | 2025-10-24 | View Filing |
| 8-K | 2025-10-21 | 2025-10-21 | View Filing |
| SC 13D/A | 2025-10-20 | 2025-10-20 | View Filing |
| 424B5 | 2025-10-17 | 2025-10-17 | View Filing |
| 424B5 | 2025-10-16 | 2025-10-16 | View Filing |
| DEFA14A | 2025-10-16 | 2025-10-16 | View Filing |
| 8-K | 2025-10-16 | 2025-10-16 | View Filing |
| DEFA14A | 2025-10-10 | 2025-10-10 | View Filing |
| 8-K | 2025-10-10 | 2025-10-10 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 3 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| S-3ASR | 2025-09-29 | 2025-09-29 | View Filing |
| DEFA14A | 2025-09-29 | 2025-09-29 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| DEFM14A | 2025-09-24 | 2025-09-24 | View Filing |
| DEFA14A | 2025-09-23 | 2025-09-23 | View Filing |
| 8-K | 2025-09-23 | 2025-09-23 | View Filing |
| SC 13D/A | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| DEFA14A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| DEFA14A | 2025-07-02 | 2025-07-01 | View Filing |
| DEFA14A | 2025-07-02 | 2025-07-01 | View Filing |
| 8-K | 2025-07-01 | 2025-07-01 | View Filing |
| DEFA14A | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| DEFA14A | 2025-06-18 | 2025-06-17 | View Filing |
| SC 13D/A | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| DEFA14A | 2025-06-03 | 2025-06-02 | View Filing |
| DEFA14A | 2025-06-02 | 2025-06-02 | View Filing |
| DEFA14A | 2025-06-02 | 2025-06-02 | View Filing |
| DEFA14A | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| SC 13G/A | 2025-05-27 | 2025-05-27 | View Filing |
| 3 | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| DEF 14A | 2025-04-21 | 2025-04-21 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| SC 13D/A | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| SC 13D | 2025-02-24 | 2025-02-24 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 8-K | 2025-02-13 | 2025-02-13 | View Filing |
| 424B5 | 2025-02-13 | 2025-02-13 | View Filing |
| 424B5 | 2025-02-12 | 2025-02-12 | View Filing |
| 8-K | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-10 | 2025-01-10 | View Filing |
| 3 | 2025-01-10 | 2025-01-10 | View Filing |
| 3 | 2025-01-10 | 2025-01-10 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 3 | 2024-12-13 | 2024-12-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 16.11% | 1 | 1078 | 0.01 | 0.02 | 36.81 |
| Williams PercentR Strategy | 9.51% | 1 | 410 | 0 | 0.02 | 30.22 |
| Keltner Channel Strategy | 9.00% | 1.03 | 163 | 0 | 0.03 | 29.71 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | x | x | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |